References
- Andreyko J. L., Blumenfeld Z., Marshall L. A., Monroe S. E., Hricak H., Jaffe R. B. Use of an agnostic analog of gonadotropin-releasing hormone (nafarelin) to treat leiomyomas. Assessment by magnetic resonance imaging. Am. J. Obstet. Gynecol. 1988; 158: 903
- Buttram V. C., Reiter R. L. Uterine leiomyomata. Etiology, symptomatology, and management. Fertil. Steril. 1981; 36: 433
- Friedman A. J., Barbieri R. L., Doubilet P. M. A randomized double blind trial of a gonadotropin hormone releasing hormone analog used in the treatment of leiomyomata uteri. Fertil. Steril. 1988; 48: 383
- Hamlin D. J., Pettersson H., Fitzsimmons J., Morgan L. S. MR imaging of uterine leiomyoma and their complications. J. Comput. Assist. Tomogr. 1985; 9: 902
- Hricak H., Tscholakoff D., Heinrichs L., et al. Uterine leiomyoma. Correlation of MR, histopathologic findings, and symptoms. Radiology 1986; 158: 385
- Ito M., Sakoda Y., Okamura H. Calcium metabolism in premenopausal women treated by GnRH agonist for uterine myoma. Endocrinol. Jpn. 1990; 37: 907
- Lee J. K. T., Gersell D. J., Balfe D. M., Worthington J. L., Picus D., Gapp G. The uterus. In vitro MR-anatomic correlation of normal and abnormal specimen. Radiology 1985; 157: 175
- Oguchi O., Mori A., Kobayashi Y., et al. Prediction of histopathologic features and proliferative activity of uterine leiomyoma by magnetic resonance imaging prior to GnRH analogue therapy. Correlation between T2-weighted images and effect of GnRH analogue. J. Obstet. Gynaecol. 1995; 21: 107
- Okizuka H., Sugimura K., Takemori M., et al. MR detection of degenerated uterine leiomyomas. J. Comput. Assist. Tomogr. 1993; 17: 760
- Shaw R. W., Fraser H. M. Use of a superactive luteinizing hormone (LHRH) agonist in the treatment of menorrhalgia. Br. J. Obstet. Gynaecol. 1984; 91: 913
- Soules M. R., McCarty K. S. Leiomyomatas. Steroid receptor content. Am. J. Obstet. Gynecol. 1982; 143: 6
- Steingold K. A., Cedars M., Lu J. K. H. Treatment of endometriosis with a long-acting gonadotropin-releasing hormone agonist. Obstet. Gynecol. 1987; 69: 403
- Uemura T., Mori J., Yoshimura Y., Minaguchi H. Treatment effects of GnRH agonist on the binding of estrogen and progesterone, and the histological findings of uterine leiomyomas. Asi-Oceania J. Obstet. Gynecol. 1991; 17: 315
- Upadhyaya N. B., Doody M., Googe P. B. Histopathologic changes in leiomyoma treated with leuprolide acetate. Fertil. Steril. 1990; 54: 811
- Weinreb J. C., Barkoff N. D., Heinrichs L. The value of MR imaging in distinguishing leiomyomas from other solid pelvic masses when sonography is indeterminate. AJR 1990; 295
- William D., Schlaff M. D., Elias A. A placebo-controlled trial of depot gonadotropin-releasing hormone analogue (leuprolide) in the treatment of uterine leiomyomata. Obstet. Gynecol. 1989; 74: 856
- Wilson E. A., Yang F., Rees E. Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissue. Obstet. Gynecol. 1980; 55: 20
- Yamashita Y., Torashima M., Takahashi M., et al. Hyperintense uterine leiomyoma at T2-weighted MR imaging. Differentiation with dynamic enhanced MR imaging and clinical implications. Radiology 1993; 189: 721
- Zawin M., McCarthy S., Scoutt L., et al. Monitoring therapy with a gonadotropin-releasing hormone analog. Utility of MR imaging. Radiology 1990; 175: 503